US FDA Staff Sees Suicidal Behavior with Sanofi-Aventis (France) Obesity Drug Zimulti

WASHINGTON, June 11 (Reuters) - Patients who took a Sanofi-Aventis SA obesity drug in clinical trials were more likely to report suicidal thoughts or actions than others who got a placebo, U.S. drug reviewers said in an analysis released on Monday.